Home LiteratureArticle Details
PMID: 82358 Published · ppublish English Case Reports Clinical Trial Journal Article

Systemic miconazole treatment of a patient with chronic granulomatous mucocutaneous candidiasis.

Acta dermato-venereologica ·Vol. 58 ·No. 5 ·1978-00-00 ·Pages 455-9

Blomqvist K, Horsmanheimo M

Abstract

Miconazole given intravenously and orally was evaluated in the treatment of a patient with drug-resistant, chronic, widespread horny candida lesions. Marked clinical improvement occurred after 4 weeks of the first course of treatment, in which 400 mg of miconazole per day was given intravenously. After 3 months no signs of the disease were apparent. The patient remained free of symptoms for 3 months, after which the lesions recurred and a second course of treatment, with 200 mg of miconazole per day intravenously, was started. A prompt clinical clearing was seen within 3 weeks, after which the miconazole (1 000 mg per day) was given orally. During oral administration of the drug a limited degree of recurrence of horny patches occurred. Systemic miconazole seems to be the drug of choice in the treatment of systemic chronic mucocutaneous candidiasis.

MeSH Terms
Administration, Oral Adolescent Candidiasis, Cutaneous/drug therapy Chronic Disease Clinical Trials as Topic Drug Evaluation Humans Imidazoles/therapeutic use Injections, Intravenous Male Miconazole/administration & dosage,therapeutic use Time Factors
Chemicals
Imidazoles Miconazole
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Blomqvist K
Horsmanheimo M
Article Info
Journal
Acta dermato-venereologica
Abbr.
Acta Derm Venereol
ISSN
0001-5555
Published
1978-00-00
Pages
455-9
Language
English
Region
Sweden
NLM ID
0370310
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com